After months of trade uncertainty, the European Commission has enacted Implementing Regulation (EU) 2022/384, enabling the resumption of fetal bovine serum (FBS) and other animal serum imports into the European Union. The decision brings relief to biotech firms, researchers, and pharmaceutical manufacturers who depend on these essential biological products for research, vaccine development, and therapeutic production.
What the Regulation Covers
Adopted on 3 March 2022, the regulation amends Annexes XIV and XV of Implementing Regulation (EU) 2021/404. It officially recognizes several third countries—such as the United States, Australia, New Zealand, and Canada—as approved sources for importing animal serum, provided the serum meets updated health and safety requirements.
Specifically, the regulation allows:
- Importation of animal serum for scientific and pharmaceutical purposes
- Clear listing of approved countries under revised animal health certificates
- A defined framework for traceability and biosafety in line with EU animal health law
Why This Regulation Matters
Prior to this update, regulatory delays and legal ambiguities had halted or severely limited serum imports into the EU. This created:
- Shortages of FBS in laboratories and manufacturing facilities
- Supply chain disruptions for clinical trials and biologics production
- Uncertainty across the life sciences sector
The new regulation re-establishes legal clarity and opens the door for regulated imports—reassuring both serum producers and end-users that compliant trade can resume.
Key Implications for the Industry
- Research continuity: EU-based laboratories can now reliably source high-quality FBS and animal sera from trusted third countries.
- Regulatory confidence: Harmonized import certificates reduce the risk of customs blocks and product seizures.
- Global trade alignment: The update strengthens scientific collaboration by aligning EU rules with those of key partner countries.
